# US 2025/0144095 A1 · Compositions and methods for treatment of connective tissue disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144095 A1
- Document ID: US20250144095A1
- Status: Published application
- Kind: A1
- Application number: 18/835,516
- Filed: 2023-02-03
- Published: 2025-05-08
- Earliest claimed: 2022-02-03
- Assignees: The Johns Hopkins University
- Applicants: The Johns Hopkins University
- Inventors: Harry C. Dietz; Caitlin J. Bowen
- Web page: https://patentgrep.com/patent/US20250144095A1

## CPC

- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/422: not condensed and containing further heterocyclic rings
- A61K 31/4523: containing further heterocyclic ring systems
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61P 19/00: Drugs for skeletal disorders
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to compositions and methods for treating vascular Ehlers Danlos Syndrome and associated connective tissue disorders.

## Claims

### Claim 1

A method of treating a connective tissue disorder, comprising:
administering a therapeutically effective amount of an agent which modulates endothelin receptor activation, expression or function, and/or inhibits endothelin-1 (ET1) expression or binding to the endothelin receptor (EDNRA/B), thereby treating the connective tissue disorder.

### Claim 2 (depends on 1)

The method of claim 1, wherein the connective tissue disorder is Ehlers-Danlos Syndrome (EDS).

### Claim 3 (depends on 2)

The method of claim 2, wherein the Ehlers-Danlos Syndrome (EDS) is hypermobile EDS, classical EDS, kyphoscoliosis EDS, arthrochalasia EDS, dermatosparaxis EDS, brittle cornea syndrome, classical-like EDS, spondylodysplastic EDS, musculocontractual EDS, myopathic EDS, periodontal EDS, cardiac-valcular EDS, or vascular EDS (vEDS).

### Claim 4 (depends on 2)

The method of claim 2, wherein the Ehlers-Danlos Syndrome (EDS) is vascular EDS.

### Claim 5 (depends on 1)

The method of claim 1, wherein the agent comprises an antibody or fragment thereof, a polypeptide, a small molecule, a nucleic acid molecule, or any combination thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein the agent inhibits endothelin-1 (ET1) expression or binding to the endothelin receptor (EDNRA/B).

### Claim 7 (depends on 1)

The method of claim 1, wherein the agent is a small molecule endothelin receptor antagonist.

### Claim 8 (depends on 1)

The method of claim 1, wherein the agent comprises bosentan, or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 8)

The method of claim 8, wherein the effective amount of the bosentan or the pharmaceutically acceptable salt thereof is from about 0.001 mg/kg to 250 mg/kg body weight.

### Claim 10 (depends on 1)

The method of claim 1, wherein the agent comprises one or more of sitaxentan, ambrisentan, macitentan and/or tezosentan.

### Claim 11 (depends on 1)

The method of claim 1, further comprising administering an agent that modulates the activity or expression of protein kinase C (PKC), mitogen-activated protein kinase (MEK) or the combination thereof.

### Claim 12 (depends on 11)

The method of claim 11, wherein a modulator of PKC activity or function is administered and comprises ruboxistaurin or pharmaceutically acceptable salts thereof.

### Claim 13 (depends on 11)

The method of claim 11, wherein a modulator of MEK activity or function in administered and comprises trametinib, binimetinib, selumetinib, cobimetinib or pharmaceutically acceptable salts thereof.

### Claim 14 (depends on 1)

The method of claim 1, further comprising administering ruboxistaurin, cobimetinib pharmaceutically acceptable salts thereof or the combination thereof.

### Claim 15 (depends on 1)

The method of claim 1, further comprising administering a modulator of type III collagen expression or function.

### Claim 16 (depends on 1)

The method of claim 1, wherein detection of ET1 signaling and/or levels of ET1, nitric oxide, nitrate, or nitrite in patient sample are indicative of vascular disease risk, progression, and/or therapeutic response in the patient.

### Claim 17

A method of treating a vascular Ehlers-Danlos Syndrome in a subject in need thereof, the method comprising: administering to the subject an effective amount of bosentan or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein the effective amount of the bosentan or the pharmaceutically acceptable salt thereof is from about 0.001 mg/kg to 250 mg/kg body weight.

### Claim 19 (depends on 17)

The method of claim 17, further comprising administering an agent for modulating expression or activity of a COL3A1 gene, correcting mutations of a COL3A1 gene or the combination thereof.

### Claim 20 (depends on 19)

The method of claim 19, wherein the agent is a gene editing agent.

### Claim 21 (depends on 17)

The method of claim 17, wherein detection of ET1 signaling and/or levels of ET1, nitric oxide, nitrate, or nitrite in patient sample are indicative of vascular disease risk, progression, and/or therapeutic response in the patient.

### Claim 22

A method of treating a vascular Ehlers-Danlos Syndrome in a subject in need thereof, the method comprising: administering to the subject an effective amount of a small molecule endothelin receptor antagonist.

### Claim 23

A method of treating a vascular Ehlers-Danlos Syndrome in a subject in need thereof, the method comprising: administering to the subject an effective amount of sitaxentan, ambrisentan, macitentan and/or tezosentan.

### Claim at position 24

24-25. (canceled)
